Duality Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Duality Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-90,881	Closed	-$1.71M	–	499
2023 Q1	$1.71M	Buy	90,881 +6,216	+7%	+$118K	0.19%	191
2022 Q4	$1.35M	Sell	84,665 -27,574	-25%	-$431K	0.15%	238
2022 Q3	$1.84M	Sell	112,239 -100,855	-47%	-$1.63M	0.2%	199
2022 Q2	$3M	Buy	213,094 +190,976	+863%	+$3.56M	0.3%	102
2022 Q1	$536K	Buy	+22,118	New	+$535K	0.06%	458
2021 Q4	–	Sell	-132,205	Closed	-$2.2M	–	468
2021 Q3	$2.2M	Buy	132,205 +121,596	+1,146%	+$2.34M	0.17%	233
2021 Q2	$259K	Sell	10,609 -5,732	-35%	-$129K	0.02%	491
2021 Q1	$422K	Sell	16,341 -12,297	-43%	-$541K	0.04%	462
2020 Q4	$1.53M	Buy	+28,638	New	+$1.42M	0.11%	267

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Duality Advisers's ACAD Position: Q2 2023 in Review

Duality Advisers sold out of Acadia Pharmaceuticals (ACAD) in Q2 2023, closing a stake of 90,881 shares — an estimated $1.71M sold.

Duality Advisers first reported a position in ACAD in Q4 2020 and held it in 9 quarters. The position peaked at $3M in Q2 2022. 236 funds tracked by Wall St. Rank hold ACAD as of Q2 2023.

Duality Advisers reported no remaining Acadia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Duality Advisers sold 90,881 Acadia Pharmaceuticals shares in Q2 2023, an estimated $1.71M.
Duality Advisers first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 9 quarters.
Duality Advisers's Acadia Pharmaceuticals position peaked at $3M in Q2 2022.
236 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2023.

Based on Duality Advisers's 13F filing for Q2 2023, filed 31 Jul 2023.